Chinese medicine formula HB01 for treating exudative age-related macular degeneration: a 6 consecutive months of clinical observation study
Chinese medicine formula HB01 for treating exudative age-related macular degeneration: a 6 consecutive months of clinical observation study作者机构:Department of Ophthalmology China-Japan Friendship Hospital Department of Graduate School Beijing University of Chinese Medicine
出 版 物:《Journal of Traditional Chinese Medicine》 (中医杂志(英文版))
年 卷 期:2017年第37卷第6期
页 面:767-773页
核心收录:
学科分类:1005[医学-中医学] 100511[医学-中医五官科学] 10[医学]
基 金:Supported by the Grant from the National Natural Science Foundation of China:Mechanism Study of Age-related Macular Degeneration Based on IL-17RC Methylation(No.81373693) Beijing Natural Science Foundation:Molecular Mechanism Underlying the Treatment of Age-related Macular Degeneration by Chinese Herbal Medicine YQTXHT Decotion Based on New Biomarker IL-17RC(No.7132196)
主 题:Macular degeneration Visual acuity Chinese medicine formula HB01
摘 要:OBJECTIVE: To evaluate the clinical efficacy of Chinese medicine formula HB01 on exudative age-related macular degeneration(AMD) patients who received HB01 for 6 months by analyzing relative ***: From July 2006 to August 2015, 139 eligible exudative AMD patients(183 eyes) were enrolled into this study and received aqueous extract from herbs of HB01 by oral twice a day(100 m L for once) for 6 months. The best corrected visual acuity, center macular thickness(CMT), hemorrhage area, fluorescein leakage area as the main outcomes were estimated and compared before and after ***: After 3 and 6 months of treatment, visual acuity obtained a greater improvement(P 0.01).After 1, 3 and 6 months of treatment, CMT obviously decreased(P 0.05). After 3 and 6 months of treatment, the hemorrhage area and fluorescein leakage area also significantly narrowed(P 0.01).During treatment, no significant adverse events relating to HB01 treatment were ***: On the basis of these results, HB01 could improve visual acuity, and reduce hemorrhage and fluorescein leakage of patients with exudative AMD, which may be an effective alternative and supportive treatment for exudative AMD.